Relay Therapeutics (NASDAQ:RLAY – Get Free Report) and CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends and profitability.
Insider and Institutional Ownership
97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by company insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Risk and Volatility
Relay Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500.
Profitability
This table compares Relay Therapeutics and CRISPR Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Relay Therapeutics | N/A | -40.25% | -36.82% |
| CRISPR Therapeutics | -1,812.07% | -25.59% | -17.89% |
Valuation & Earnings
This table compares Relay Therapeutics and CRISPR Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Relay Therapeutics | $15.35 million | 260.40 | -$276.48 million | ($1.51) | -11.98 |
| CRISPR Therapeutics | $3.51 million | 1,167.32 | -$581.60 million | ($4.74) | -8.91 |
Relay Therapeutics has higher revenue and earnings than CRISPR Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Relay Therapeutics and CRISPR Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Relay Therapeutics | 1 | 1 | 11 | 1 | 2.86 |
| CRISPR Therapeutics | 1 | 6 | 8 | 2 | 2.65 |
Relay Therapeutics presently has a consensus target price of $27.00, indicating a potential upside of 49.25%. CRISPR Therapeutics has a consensus target price of $72.93, indicating a potential upside of 72.65%. Given CRISPR Therapeutics’ higher probable upside, analysts plainly believe CRISPR Therapeutics is more favorable than Relay Therapeutics.
About Relay Therapeutics
Relay Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines for patients with serious diseases, with an emphasis on cancer. The company uses its computational drug discovery platform to study how proteins move and interact, aiming to identify drug targets and design therapies against them. Relay’s research combines experimental biology, structural biology and computational methods. Its drug development programs have included candidates targeting cancer-related pathways, such as FGFR2 and PI3K?.
About CRISPR Therapeutics
CRISPR Therapeutics AG is a biotechnology company focused on developing gene-based medicines using CRISPR/Cas9, a gene-editing technology that can make targeted changes to DNA. Founded in 2013, the company is headquartered in Zug, Switzerland, and maintains U.S. operations in Cambridge, Massachusetts. Its lead product, Casgevy (exa-cel), was developed with Vertex Pharmaceuticals for people with sickle cell disease and transfusion-dependent beta thalassemia. It was the first therapy based on CRISPR gene editing to receive regulatory approval.
Receive News & Ratings for Relay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
